申请人:Zeneca Limited
公开号:US05563141A1
公开(公告)日:1996-10-08
A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.
一种通式为(M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物,其中:n为0或1;M.sup.1为氨基基团;Q为含有碱性氮原子的芳香杂环基团;M.sup.2为亚胺基团;L为模板基团;A为酸性基团,或其酯或酰胺衍生物,或磺酰胺基团;以及其医药上可接受的盐和前药,用于治疗与 GPIIb-IIIa 结合的粘附分子介导的血小板聚集相关的疾病。还公开了新型化合物。